Literature DB >> 9450240

Application of liposomes for development of oral vaccines: study of in vitro stability of liposomes and antibody response to antigen associated with liposomes after oral immunization.

M Han1, S Watarai, K Kobayashi, T Yasuda.   

Abstract

In order to evaluate the usefulness of liposomes as oral vaccines, the stability of liposomes and serum IgA antibody response to antigen associated with liposomes after oral administration were examined. Liposomes composed of dipalmitoylphosphatidylcholine (DPPC), dipalmitoylphosphatidylserine (DPPS), and cholesterol (Chol) (1:1:2, molar ratio), distearoylphosphatidylcholine (DSPC) and Chol (7:2, molar ratio), and DSPC, DPPS, and Chol (7:3:2 or 1:1:2, molar ratio) were stable in acidic solution (pH 2.0), bile, and pancreatin solution, whereas liposomes composed of DPPC and Chol (7:2, molar ratio) and DPPC, DPPS, and Chol (7:3:2, molar ratio) were unstable in pH 2.0 and/or bile solutions. After the oral immunization of antigen (ganglioside GM1)-containing liposomes composed of DPPC, DPPS, and Chol (1:1:2, molar ratio) to mice, the serum IgA antibody responses against ganglioside GM1 were found. Furthermore, when monophosphoryl lipid A was incorporated into liposomes containing ganglioside GM1, further augmentation of IgA responses to ganglioside GM1 was observed. On the other hand, the oral administration with liposomes composed of DPPC, Chol, and ganglioside GM1 (unstable liposomes), ganglioside GM1 mixed with liposomes composed of DPPC, DPPS and Chol, and ganglioside GM1 alone was unable to induce any detectable anti-ganglioside GM1 IgA antibody responses. These results suggest that liposomes which showed the stability to acidic solution, bile, and pancreatin solution would serve effectively as an oral delivery vehicle for inducing mucosal immune responses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9450240     DOI: 10.1292/jvms.59.1109

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


  5 in total

1.  Efficiency of pH-sensitive fusogenic polymer-modified liposomes as a vaccine carrier.

Authors:  Shinobu Watarai; Tana Iwase; Tomoko Tajima; Eiji Yuba; Kenji Kono
Journal:  ScientificWorldJournal       Date:  2013-02-04

Review 2.  Mucosal Vaccine Development Based on Liposome Technology.

Authors:  Valentina Bernasconi; Karin Norling; Marta Bally; Fredrik Höök; Nils Y Lycke
Journal:  J Immunol Res       Date:  2016-12-29       Impact factor: 4.818

Review 3.  Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.

Authors:  Blaise Corthésy; Gilles Bioley
Journal:  Front Immunol       Date:  2018-03-07       Impact factor: 7.561

4.  Evaluation of pH-sensitive fusogenic polymer-modified liposomes co-loaded with antigen and α-galactosylceramide as an anti-tumor vaccine.

Authors:  Seiji Okazaki; Tadashi Iwasaki; Eiji Yuba; Shinobu Watarai
Journal:  J Vet Med Sci       Date:  2017-12-28       Impact factor: 1.267

5.  Mimicking Native Display of CD0873 on Liposomes Augments Its Potency as an Oral Vaccine against Clostridioides difficile.

Authors:  Cansu Karyal; Panayiota Palazi; Jaime Hughes; Rhys C Griffiths; Ruby R Persaud; Patrick J Tighe; Nicholas J Mitchell; Ruth Griffin
Journal:  Vaccines (Basel)       Date:  2021-12-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.